Interesting ARQT Put And Call Options For September 18th

Arcutis Biotherapeutics (ARQT) option ideas: a $15.00 put with a $0.10 bid would obligate purchase at $15.00 (net cost basis $14.90 vs. current $25.71) and is ~42% out-of-the-money with models implying an 86% chance to expire worthless, yielding 0.67% (1.01% annualized) if it does. On the call side, a $40.00 call bid at $1.35 sold as a covered call against shares bought at $25.71 would cap upside at $40 but deliver a 60.83% total return if called at the Sept. 18 expiration; the $40 strike is ~56% out-of-the-money with a 63% probability to expire worthless, equating to a 5.25% (7.95% annualized) YieldBoost. Implied volatilities are ~107% for the put and 83% for the call versus a trailing 12-month volatility of 62%; StockOptionsChannel will track odds and contract histories on its site.

Analysis

Market structure: The option quotes favor volatility sellers and market-makers — put buyers demand protection (puts IV 107% vs spot 62% realized) while call IV is 83%, implying asymmetric downside fear for ARQT (current price $25.71). Direct winners are cash‑rich investors willing to be long equity at deep OTM strikes ($15) or collect premium via covered calls; losers are holders who need immediate upside beyond $40 or who are short gamma into catalysts.

Risk assessment: Tail risk is idiosyncratic (trial failure or FDA negative action) that can erase >60% of market value — implied vol premium prices that risk. Near term (days–weeks) the dominant risks are event-driven spikes; short-to-medium (months) risks are liquidity and early assignment on foreign flows; long term depends on pipeline approvals and commercial execution.

Trade implications: Favor selling defined-risk volatility rather than naked directional exposure. Practical plays include cash‑secured $15 puts (high probability, small yield) or buying the shares and selling Sep-18 $40 calls to capture ~5.25% immediate yield and 60.8% capped upside. If you want more protection, use put credit spreads ($15/$12.50 Sep) to limit max loss to ~$2.40/contract.

Contrarian angles: The market is overpricing short-term downside (put IV > realized by ~45ppt), creating edge for disciplined premium sellers with strict size limits. Consensus underweights binary upside (FDA surprise), so asymmetric, small-sized long-biotech exposures (long equity + short XBI hedge) can capture idiosyncratic rerating if a positive catalyst lands within 3–6 months.

Key Decisions for Investors

• Sell cash‑secured ARQT Sep‑18 $15 puts sized to <=1.0% NAV (one contract ≈ $1,500 cash commitment); collect $0.10 premium for a 0.67% yield on commitment (annualized ~1.0%); only deploy if willing to own at $14.90 and exit/reduce 2 trading days before any known catalyst.
• If you prefer defined risk, sell Sep‑18 ARQT $15/$12.50 put credit spreads sized to <=1.5% NAV; max loss = $2.40 per spread, target credit ~ $0.10; roll or close if spread value >50% of max loss before expiration.
• Establish a buy‑write: buy ARQT up to 2.0% NAV at market (~$25.71) and sell Sep‑18 $40 calls for $1.35 to capture ~5.25% immediate premium and 60.8% upside to $40; use a stop‑loss at 30% drawdown or trim on positive catalyst news within 90 days.
• Pair trade for idiosyncratic exposure: long ARQT equity (0.5–1.0% NAV) and short XBI ETF 50% notional to hedge sector beta; rebalance post any ARQT trial/FDA event within a 3–6 month window.